Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

inflammation · Mechanism Report

Do low EPA and low omega-3 status reduce pro-resolving mediator production and favor unresolved inflammation?

Low EPA and low total omega-3 status reduce EPA-derived pro-resolving mediator synthesis and shift lipid signaling toward less-resolved inflammation.

PlausibleJuly 20, 202611 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

Low EPA and low total omega-3 status reduce substrate availability for EPA-derived specialized pro-resolving mediators and shift lipid signaling toward less-resolved inflammation.

laying out figure…
1 of 3 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim says that when EPA and overall omega-3 status are low, the substrate pool for E-series resolvins is restricted. It also frames this as an imbalance in lipid signaling, with a higher AA:EPA ratio favoring more pro-inflammatory mediators and less effective inflammation resolution.

Verified conclusion

Systemic inflammation resolution is an active, biochemically controlled process that depends on the availability of essential fatty acid precursors. Omega-3 status, particularly eicosapentaenoic acid (EPA) levels, directly dictates the body's capacity to synthesize the signaling molecules required to terminate inflammatory responses.

Mechanistic pathways of resolution

  • Precursor limitations: EPA is the obligate precursor for E-series resolvins (RvE1–RvE4), which are specialized pro-resolving mediators (SPMs).
  • Enzymatic cascade: Under normal conditions, EPA is oxygenated by aspirin-acetylated COX-2 or cytochrome P450 to yield the intermediate 18-hydroxyeicosapentaenoic acid (18-HEPE). This intermediate is further metabolized by 5-lipoxygenase (5-LOX) to generate RvE1 and RvE2, or by 15-LOX to produce RvE3 and RvE4.
  • Biosynthetic bottleneck: A low systemic omega-3 index restricts the pool of free EPA, directly limiting 18-HEPE production and creating a structural ceiling on resolvin synthesis, even when downstream enzymes are fully active.

Lipid signaling and enzyme competition

  • Substrate competition: EPA and arachidonic acid (AA) compete for the same cyclooxygenase (COX) and lipoxygenase (LOX) enzymes.
  • Pro-inflammatory skew: A low omega-3 status elevates the systemic AA:EPA ratio. This shift favors the production of highly inflammatory AA-derived eicosanoids, such as prostaglandin E2 (PGE2) and leukotrienes, over less inflammatory counterparts like PGE3.
  • Impaired class switching: This competitive imbalance prevents "lipid mediator class switching"—the transition from initiating inflammation to actively resolving it—leaving the signaling network locked in a chronic, unresolved state.

Bottom line

  • Low EPA and total omega-3 status restrict the essential precursor pool (18-HEPE) for E-series resolvins and elevate the AA:EPA ratio, competitively shifting cellular signaling away from inflammatory resolution and toward a persistent, unresolved state.

References

  1. E-series resolvin metabolome, biosynthesis and critical role ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  2. Relationship Between the Omega-3 Index and Specialized Pro ... — pmc.ncbi.nlm.nih.gov ↗
  3. E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition — linkinghub.elsevier.com ↗
  4. Why Spm Deficiency Drives... — drseinfeld.shop ↗
  5. A New E-Series Resolvin: RvE4 Stereochemistry and Function in ... — frontiersin.org ↗
  6. The eicosapentaenoic acid:arachidonic acid ratio and its clinical ... — tandfonline.com ↗
  7. Bioactive Lipids and Chronic Inflammation: Managing the Fire Within — frontiersin.org ↗
  8. Concentration and ratio of essential fatty acids influences ... — sciencedirect.com ↗
  9. The Anti-inflammatory Effect of Personalized Omega-3 Fatty Acid Dosing for Reducing Prostaglandin E2 in the Colonic Mucosa Is Attenuated in Obesity — aacrjournals.org ↗
  10. What Your AA:EPA Ratio Is Telling You About Systemic ... — lamkinclinic.com ↗
  11. The Role of Eicosanoids in Atherosclerosis — ahajournals.org ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesCan hs-CRP reflect low-grade systemic inflammation even within the normal range?→Plausible8 sourcesCan rs1420101 CT, rs20541 AG, and rs1801275 AG contribute to type 2 eosinophilic airway inflammation susceptibility?→